← Back to Search

Virtual Reality Therapy for ADHD

Phase 1 & 2
Recruiting
Led By Susan Persky, Ph.D.
Research Sponsored by National Human Genome Research Institute (NHGRI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within one month of the end of vr training
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if virtual reality games can help children with ADHD improve their thinking skills and brain function. Participants will play these games to practice focusing, controlling impulses, processing information quickly, and remembering things better. The goal is to see if these games can make a positive difference in their daily lives.

Who is the study for?
This trial is for children aged 7 to 14 with ADHD, who can follow the study's procedures and are stable on medication if they're taking any. It excludes those with cognitive impairments, severe migraines, vertigo, epilepsy or serious balance disorders, poor uncorrected vision, pregnancy, psychotic disorders or substance dependence.
What is being tested?
The trial tests a virtual reality-based game using Floreo VR applications designed to improve attention and cognitive skills in kids with ADHD. Participants play games that target specific skills like inhibition control for several weeks while their brain function is monitored.
What are the potential side effects?
Potential side effects from participating in this trial include motion sickness, eye strain or headaches as reported by participants during weekly interviews.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within one month of the end of vr training
This trial's timeline: 3 weeks for screening, Varies for treatment, and within one month of the end of vr training for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ADHD-RS-5 inattention sub-scale.
Secondary study objectives
Matrix Bands
Number of correct responses on the NIH Toolbox Pattern Comparison Processing Speed Test.
Stop signal reaction time on the Stop Signal task (inhibitory control)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Floreo VR groupExperimental Treatment1 Intervention
This group will undergo up to 20 daily sessions (20 minutes each) of the Floreo VR training.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ADHD include stimulant medications, behavioral therapy, and cognitive training. Stimulant medications, such as methylphenidate and amphetamines, work by increasing the levels of dopamine and norepinephrine in the brain, which helps improve attention and reduce impulsivity and hyperactivity. Behavioral therapy focuses on modifying behavior through reinforcement strategies. Cognitive training, including virtual reality-based games, aims to enhance cognitive skills like working memory, processing speed, and inhibitory control through repeated practice and stimulation. These treatments are crucial for ADHD patients as they address core symptoms and improve daily functioning, educational outcomes, and social interactions.
A Virtual Reality Serious Videogame Versus Online Chess Augmentation in Patients with Attention Deficit Hyperactivity Disorder: A Randomized Clinical Trial.Comparing the Effects of Drug Therapy, Perceptual Motor Training, and Both Combined on the Motor Skills of School-Aged Attention Deficit Hyperactivity Disorder Children.Psychosocial treatments for adults with attention-deficit/hyperactivity disorder.

Find a Location

Who is running the clinical trial?

National Human Genome Research Institute (NHGRI)Lead Sponsor
270 Previous Clinical Trials
294,055 Total Patients Enrolled
3 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
5,672 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Susan Persky, Ph.D.Principal InvestigatorNational Human Genome Research Institute (NHGRI)
8 Previous Clinical Trials
4,522 Total Patients Enrolled
Wallace P Shaw, M.D.Principal InvestigatorNational Human Genome Research Institute (NHGRI)
2 Previous Clinical Trials
2,191 Total Patients Enrolled
2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
2,191 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

Floreo Virtual Reality application Clinical Trial Eligibility Overview. Trial Name: NCT05608434 — Phase 1 & 2
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Floreo VR group
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Floreo Virtual Reality application Highlights & Side Effects. Trial Name: NCT05608434 — Phase 1 & 2
Floreo Virtual Reality application 2023 Treatment Timeline for Medical Study. Trial Name: NCT05608434 — Phase 1 & 2
~136 spots leftby Dec 2025